Westport-based BioSig Technologies regains full compliance for Nasdaq listing
Contributed
BioSig Technologies Inc. develops medical technology like the Pure EP, which measures cardiac signals.
Five months after being granted a reprieve from being delisted, Westport-based BioSig Technologies said Tuesday it has regained full compliance to be listed on the Nasdaq stock market.
According to a filing with the U.S. Securities and Exchange Commission (SEC), BioSig was notified on Monday that it has “successfully met the qualifications to regain full compliance for continued listing” on Nasdaq.
The company had been notified on Oct. 18, 2024, by Nasdaq that the Nasdaq listing and hearing review council had granted it an exception through March 7 to provide evidence it met the compliance requirements — either maintaining $35 million in the market value of listed securities or $2.5 million in stockholders’ equity.
“On March 6, 2025, the (c)ompany submitted documents to Nasdaq evidencing its compliance with the Equity Rule and had awaited Nasdaq’s formal confirmation,” the SEC filing states.
The company, which is based at 55 Greens Farms Road in Westport and develops signal-processing equipment that can diagnose heart malfunctions, had been informed on June 10 last year that its stock would be delisted due to the company’s “continued non-compliance with the minimum stockholders’ equity requirement” set by the market.
Trading in the company’s common stock was subsequently suspended on June 12, though Nasdaq said at the time that the stock “should be eligible” to trade on the over-the-counter market’s “Pink Current Information tier,” or OTCPK.
As of Tuesday morning, the stock was trading again on the Nasdaq at 52 cents per share, according to Yahoo Finance, which also set BioSig’s market capitalization at $9.14 million.
Most Recent
Most Recent
0 Comments